Inflammation in biopsy specimen tied to lower risk of prostate cancer diagnosis
The risk of prostate cancer diagnosis is low in the presence of inflammation, as established by needle biopsy, according to a recent study.
Researchers conducted a literature review and meta-analysis of cohort or case-control studies that involved adult participants with histologic inflammation on prostate needle biopsy. They searched multiple electronic databases for abstracts containing the keywords prostate cancer, inflammation, and biopsy.
Pooled data from 25 studies, comprising 20,585 participants and 6,641 prostate cancer cases, showed the presence of any inflammation to be significantly associated with a lower risk of prostate cancer diagnosis (odds ratio [OR], 0.455; 95 percent CI, 0.337–0.573).
When analysis was stratified by type of inflammation, the risk of prostate cancer diagnosis was low in the presence of either acute (OR, 0.681; 0.450–0.913; four studies) or chronic inflammation (OR, 0.499; 0.334–0.665; 15 studies).
There was a significant heterogeneity among studies (I2, 84.4 percent; p<0.001) and no evidence of publication bias (p>0.05).
In previous studies, inflammation in the biopsy specimen has also been reported to lower the risk of subsequent prostate cancer diagnosis on repeat biopsy, as well as be associated with less aggressive prostate cancer. Some experts postulate that such association may be explained by the potential cellular preference of inflammation signalling pathways rather than carcinogenesis. As a consequence, progression of the malignance might be interrupted and the risk of prostate cancer is reduced. [Cancer 2014;120:190–196; Prostate 2015;75:1492–1498; Curr Urol 2016;9:82–92]